Related Articles
Interval between hepatocellular carcinoma treatment and interferon‑free direct‑acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence
Absence of differences in the recurrence rates of hepatitis C virus‑associated hepatocellular carcinoma between direct‑acting antivirals and interferon‑based treatments: A multicenter study
FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy
Sustained virological response by direct‑acting antivirals reduces the recurrence risk of hepatitis C‑related hepatocellular carcinoma after curative treatment
Direct‑acting antiviral treatment decreases serum undercarboxylated osteocalcin in male patients with chronic hepatitis C